Psomagen소마젠

Psomagen returned to a small TTM operating profit in H1 2026 after years of losses, but the stock has fallen sharply over the past year.

Psomagen, a Korean-listed genome sequencing services company selling mainly to research, pharma and biotech customers in North America, reported trailing-twelve-month revenue of ₩37.3B and operating income of ₩956M for the period to H1 2026. The shares closed at ₩2,730, down 21% over one year, and the data shows no dividend and no borrowings.

What stands out

• Revenue reached ₩38.7B in 2025 after ₩31.0B in 2024, but the company still posted a net loss of ₩660M in 2025.
• Trailing figures to H1 2026 show a 2.6% operating margin and 5.3% net margin, against negative margins in each year from 2021 to 2024.
• Cash of ₩6.1B and zero borrowings are recorded, with trailing free cash flow of ₩3.6B.
• Valuation multiples are extremely high (P/E about 26,773 on trailing earnings), reflecting very thin reported profits rather than a typical market rating.
• Recent headlines cite additional research funding projects of about ₩5B and $3.72M, and a Money Today piece discusses expected benefits from the US NDAA; the data does not explain these in detail.

What to watch

• The next half-year or quarterly filings, to see whether the H1 2026 operating profit is sustained.
• The major management matter filed on 2026-06-30, whose content is not described in the data.
• Foreign and institutional holdings: foreign ownership is recorded at 0%, and 20-day investor flows show retail net selling of about ₩88.6B.